May 4, 2026
Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) in head-to-head trial data. The SURMOUNT-5 trial (2025) found tirzepatide reduced body weight by approximately 20.2% vs. 13.7% for semaglutide over 72 weeks. Both are FDA-approved injectable medications for chronic weight management, but they work through different receptor mechanisms, follow different dosing schedules, and carry […]